访问全球数据，解决罕见疾病：健康经济学价值框架（英文版）_28页_1mb

Summary of "Global Data Access for Solving Rare Disease: A Health Economics Value Framework"

Core Content

This document explores the potential economic and societal value of federated data systems in addressing the challenges of rare diseases. Rare diseases, though individually uncommon, collectively affect 10% of the global population (approximately 475 million people), with 80% of them being genetic in origin. The diagnostic odyssey—the prolonged search for a diagnosis—averages seven years and leads to high costs and emotional distress for patients and their families. The document emphasizes the importance of genomic and clinical data sharing to improve diagnosis, treatment, and overall patient outcomes, while also addressing the ethical and legal challenges of data privacy and access.

Main Points

1. Federated Data Systems: A Solution for Rare Disease

• A federated data system is a meta-database that connects multiple independent databases without merging them, preserving data privacy and local autonomy.
• It enables global access to rare-disease data while respecting regional and cultural data protection standards.
• The system is decentralized, using application programming interfaces (APIs) to ensure interoperability and secure access.

2. Economic and Societal Benefits

• Diagnostic benefit: Federated data systems can reduce the average time to diagnosis and reclassify variants of unknown significance, leading to cost savings and improved patient outcomes.
• Clinical benefit: A diagnosis allows for targeted treatment and better management of care, which can significantly improve health outcomes.
• Clinical trial benefit: Federated data systems can accelerate clinical trial processes by enabling data-driven insights and more efficient trial design.
• Personal benefit: Access to information can improve family planning, quality of life, and emotional well-being for patients and their caregivers.

3. Challenges and Gaps in Data Sharing

• Legal and regulatory barriers such as GDPR in the EU and HIPAA in the US make direct data sharing difficult.
• Evidentiary gaps exist in quantifying the economic impact of federated data systems, especially in long-term cost savings and non-medical cost implications.
• The cost of building a federated data system for genomic data can be high, especially when data restructuring is required.

4. Case Studies and Real-World Impact

• Heather Renton (Australia): Describes the emotional and financial toll of a nine-year diagnostic journey, highlighting the lack of government funding for genomic testing.
• Krissa Harris (USA): Emphasizes the ongoing burden on caregivers and the psychological impact of prolonged diagnosis.
• Lynsey Chediak (USA): Illustrates the high cost of diagnostic and therapeutic interventions and the futility of untracked costs.
• Sarah and Kane Blackman (Australia): Reflect on the emotional impact of a late diagnosis and the importance of early intervention.
• Durhane Wong-Rieger (Canada): Shares the personal journey of a family with two children affected by rare diseases, emphasizing the value of a diagnosis.

Key Information

• Global impact: Rare diseases affect 10% of the global population and 7,000+ identified conditions.
• Diagnostic delay: The average time to diagnosis is seven years, with 40–60% of patients still undiagnosed.
• Economic burden: The UK’s NHS spent $19.6 billion on rare diseases in 2016, with $4.4 billion attributed to 258,235 patients over a 10-year period.
• Cost of diagnosis: A diagnostic odyssey can cost $2,190 in the first year and $592 per additional year, with travel and caregiver costs also significant.
• Drug repurposing: This approach is 30% more successful than traditional R&D and is cost-effective (around $250,000 vs. $1.5 billion).
• Orphan drugs: 51% of FDA-approved orphan drugs were developed since 2010, with drug repurposing contributing to 47% of these designations.
• Gene therapies: These novel treatments for genetic conditions can be accelerated and optimized through federated data systems.

Conclusion

The document concludes that federated data systems offer a promising solution for global rare disease research and care delivery, with the potential to improve diagnostic accuracy, reduce costs, and enhance patient outcomes. However, it stresses the need for a robust value framework to justify the investment in these systems. The economic benefits of such systems are substantial, but further research and collaboration are required to fully quantify and realize these benefits.

Call to Action

• Investment in federated data systems is needed to test and confirm their value propositions.
• Collaboration across nations and healthcare systems is essential to overcome regulatory and data-sharing barriers.
• Further research is required to understand the full economic impact of federated data systems, including non-medical costs and long-term benefits.